EQT agrees to buy molecular testing firm Qiagen for $10.8 billion

Bloomberg reports EQT has agreed to buy molecular testing company Qiagen for around €9.6 billion ($10.8 billion), ending years of takeover speculation. Qiagen's board approved the €46.50-a-share, all-cash offer by a holding company indirectly controlled by an EQT fund. Affiliates of the Abu Dhabi Investment Authority and Canada Pension Plan Investment Board are participating in the offer.